



## mRNA Vaccines: Pioneering the Future of Vaccination

Guest Editors:

### Dr. Zhongfeng Ye

Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA

### Dr. Yu Zhao

Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA

### Dr. Minghui Yang

Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan

Deadline for manuscript submissions:

**31 January 2025**

### Message from the Guest Editors

Amid the devastation of the COVID-19 pandemic, mRNA vaccines have risen to the occasion. While early IVT-mRNA was limited by instability, high immunogenicity, and poor translatability, current advances in mRNA synthesis have significantly enhanced antigen expression and protective immunity.

The impact of mRNA vaccines on cancer and infectious disease remains in its preliminary stages. Trials in animal-based models and human individuals exhibit substantial differences in expression and immune response. The mechanisms of these vaccines in animal models and humans also require further investigation.

To achieve a more extensive understanding of the recent scientific knowledge and current trends in mRNA vaccine development, this Special issue is focused on the recent scientific and technical advances including, but not limited to, mRNA vaccines. Based on your extensive knowledge and experience, we invite you to contribute an original report, original observation or review.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)